Literature DB >> 15671773

Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior.

Rosa Paula Biscolla1, Clara Ugolini, Mariangela Sculli, Valeria Bottici, Maria Grazia Castagna, Cristina Romei, Barbara Cosci, Eleonora Molinaro, Pinuccia Faviana, Fulvio Basolo, Paolo Miccoli, Furio Pacini, Aldo Pinchera, Rossella Elisei.   

Abstract

Papillary thyroid microcarcinoma (mPTC), is a very frequent incidental finding with a frequency varying from a few percent to 35% at postmortem histopathologic examinations. However, the presence of mPTC in patients undergoing thyroidectomy for multinodular goiter (MNG) and for Graves' disease (GD) has been found to be lower. Patients with medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) association have been published as anecdotal case reports, as well as kindred with familial MTC or multiple endocrine neoplasia (MEN) 2A with some members simultaneously affected by MTC and PTC. We studied the prevalence and the biological behavior of MTC associated with PTC, with particular attention to those cases in which a mPTC was incidentally found. Twenty-seven of 196 (13.8%) MTC cases showed an association with PTC and in particular 21 of 190 (11.05%) with an incidental mPTC. This percentage is higher than that reported in the literature on the association of mPTC with GD (2.8%-4.5%) and MNG (3%). Also the percentage of the more general association of MTC/PTC, not restricted to mPTC, found in our series (13.8%) is higher than that reported in studies that analyzed the prevalence of PTC (any size) in patients treated for MNG (7.5%). A similarly high percentage of MTC/PTC had not been reported before and in particular there are no reports on large series of MTC/PTC. We also analyzed the epidemiologic, clinical, and pathologic features of MTC associated and not associated with PTC without finding any difference. In particular the outcome of the MTC did not appear to be influenced by the presence of the PTC and the specific radioiodine treatments. Moreover, although we cannot completely exclude a shared pathogenic event as the cause of both MTC and PTC, the molecular analysis of RET gene alterations did not show any common mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15671773     DOI: 10.1089/thy.2004.14.946

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  18 in total

Review 1.  Synchronous medullary, papillary and follicular carcinomas in the same thyroid: case report and review of literature.

Authors:  Daunia Verdi; Gianmaria Pennelli; Francesca Galuppini; Maria Rosa Pelizzo; Antonio Toniato
Journal:  Updates Surg       Date:  2012-04-13

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.

Authors:  Christopher Griffith; Shengle Zhang; Sanjay Mukhopadhyay
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

Review 4.  Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment.

Authors:  Shabina R Ahmed; Douglas W Ball
Journal:  J Clin Endocrinol Metab       Date:  2011-02-23       Impact factor: 5.958

5.  Synchronous papillary thyroid carcinoma and follicular thyroid carcinoma: case report and review of literature.

Authors:  Jia-Wei Feng; Jing Ye; Jun Hu; Sheng-Yong Liu; Yong Jiang; Li-Zhao Hong
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

6.  Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Authors:  R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei
Journal:  J Endocrinol Invest       Date:  2016-08-17       Impact factor: 4.256

7.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

Review 8.  Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Authors:  Maria Alevizaki; Elena Kyratzoglou; Aristoteles Bamias; Marinella Tzanela; Meletios A Dimopoulos; Katerina Saltiki
Journal:  Endocrine       Date:  2013-04-23       Impact factor: 3.633

Review 9.  Familial non-medullary thyroid carcinoma: an update.

Authors:  Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer.

Authors:  Jen-Der Lin
Journal:  Med Oncol       Date:  2009-06-09       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.